Abstract
Adipose tissue sits at the crossroads of metabolism. It actively participates in the day-to-day regulation of energy balance, and it is the largest reservoir of energy for long-term needs. The human body is designed to sense its current energy status. Fuel sensors are located in the abdominal cavity along the digestive tract but also in adipose tissue. Afferent signals from these sensors reach the central nervous system in the form of neural and hormonal inputs. The brain directs action to maintain a steady intake of nutrients and energy.
An overarching principle is that there are regulatory and counter-regulatory systems which are constantly operating, and the ratio of them is what determines the outcome. An example of this is the ratio of insulin to glucagon in the venous drainage of the pancreas, which determines the response of the liver acutely. Another example is the leptin to adiponectin ratio in the venous drainage of intra-abdominal (visceral) adipose tissue, which signals the liver and brain on the status of energy stores and adipose tissue function.
Constant fuel signaling allows the body access to nutrients. When access to nutrients is not possible, the body engages metabolic pathways to compensate. Long-term derangements of fuel acquisition cause profound alterations in the signaling pathways and allow the body to survive longer. Both anorexic diseases at one extreme and obesity on the other are characterized by changes from normal physiology. In the case of obesity, for example, there is a significant rise in the leptin to adiponectin ratio. This signals the brain that there are excess calories in storage and that adipose tissue function is compromised. Understanding these metabolic relationships allows for the development of targeted treatments for chronic diseases of metabolism.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Reading List
Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94(6):1843–52. Epub 2009/04/02.
Bays HE, Gonzalez-Campoy JM. Adiposopathy. In: Friedberg E, Castrillon DH, Galindo RL, Wharton K, editors. New-Opathies: World Scientific; 2012. p. 105–68.
Breen DM, Rasmussen BA, Cote CD, Jackson VM, Lam TK. Nutrient-sensing mechanisms in the gut as therapeutic targets for diabetes. Diabetes. 2013;62(9):3005–13. Epub 2013/08/24.
Broeders EP, Vijgen GH, Havekes B, Bouvy ND, Mottaghy FM, Kars M, et al. Thyroid hormone activates brown adipose tissue and increases non-shivering thermogenesis—a cohort study in a Group of Thyroid Carcinoma Patients. PLoS One. 2016;11(1):e0145049. Epub 2016/01/20.
Brubaker PL. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology. 2010;151(5):1984–9. Epub 2010/03/23.
Cantini G, Di Franco A, Mannucci E, Luconi M. Is cleaved glucagon-like peptide 1 really inactive? Effects of GLP-1(9–36) on human adipose stem cells. Mol Cell Endocrinol. 2017;439:10–5. Epub 2016/10/30.
Chakraborti CK. Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity. World J Diabetes. 2015;6(15):1296–308. Epub 2015/11/12.
Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J Biol Chem. 2012;287(9):6421–30. Epub 2011/12/31.
D’Aquila T, Hung YH, Carreiro A, Buhman KK. Recent discoveries on absorption of dietary fat: presence, synthesis, and metabolism of cytoplasmic lipid droplets within enterocytes. Biochim Biophys Acta. 2016;1861(8 Pt A):730–47. Epub 2016/04/25.
DePaoli AM. 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J Endocrinol. 2014;223(1):T71–81. Epub 2014/06/29.
Esfahani M, Movahedian A, Baranchi M, Goodarzi MT. Adiponectin: an adipokine with protective features against metabolic syndrome. Iranian J Basic Med Sci. 2015;18(5):430–42. Epub 2015/07/01.
Farooqi IS, O’Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol. 2014;223(1):T63–70. Epub 2014/09/19.
Glasow A, Bornstein SR. Leptin and the adrenal gland. Eur J Clin Investig. 2000;30(Suppl 3):39–45. Epub 2001/04/03.
Gurriaran-Rodriguez U, Al-Massadi O, Roca-Rivada A, Crujeiras AB, Gallego R, Pardo M, et al. Obestatin as a regulator of adipocyte metabolism and adipogenesis. J Cell Mol Med. 2011;15(9):1927–40. Epub 2010/10/30.
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–36. Epub 2016/12/17.
Kargi AY, Iacobellis G. Adipose tissue and adrenal glands: novel pathophysiological mechanisms and clinical applications. Int J Endocrinol. 2014;2014:614074. Epub 2014/07/16.
Kawwass JF, Summer R, Kallen CB. Direct effects of leptin and adiponectin on peripheral reproductive tissues: a critical review. Mol Hum Reprod. 2015;21(8):617–32. Epub 2015/05/13.
Lacquaniti A, Donato V, Chirico V, Buemi A, Buemi M. Obestatin: an interesting but controversial gut hormone. Ann Nutr Metab. 2011;59(2–4):193–9. Epub 2011/12/14.
Liao YC, Liang KW, Lee WJ, Lee WL, Lee IT, Wang JS, et al. Leptin to adiponectin ratio as a useful predictor for cardiac syndrome X. Biomarkers: Biochem Indicators Exposure Response Susceptibility Chem. 2013;18(1):44–50. Epub 2012/10/17.
Liu R, Li L, Chen Y, Yang M, Liu H, Yang G. Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis. Ann Med. 2014;46(8):664–71. Epub 2014/08/20.
Lopez-Jaramillo P, Gomez-Arbelaez D, Lopez-Lopez J, Lopez-Lopez C, Martinez-Ortega J, Gomez-Rodriguez A, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Invest. 2014;18(1):37–45. Epub 2014/11/13.
Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011;301(4):E567–84. Epub 2011/07/28.
Muller MJ, Enderle J, Bosy-Westphal A. Changes in energy expenditure with weight gain and weight loss in humans. Curr Obes Rep. 2016;5(4):413–23. Epub 2016/10/16.
Nayak S, Bhaktha G, Mohammed S. Adiponectin in diabetic subjects without any micro- or macrovascular complications: a review. J Diabetes Sci Technol. 2015;9:1160. Epub 2015/04/26
Nerup N, Ambrus R, Lindhe J, Achiam MP, Jeppesen PB, Svendsen LB. The effect of glucagon-like peptide-1 and glucagon-like peptide-2 on microcirculation: a systematic review. Microcirculation. 2017; Epub 2017/03/08.
Obregon MJ. Adipose tissues and thyroid hormones. Front Physiol. 2014;5:479. Epub 2015/01/08.
Park JT, Yoo TH, Kim JK, Oh HJ, Kim SJ, Yoo DE, et al. Leptin/adiponectin ratio is an independent predictor of mortality in nondiabetic peritoneal dialysis patients. Perit Dial Int. 2013;33(1):67–74. Epub 2012/08/03.
Pruszynska-Oszmalek E, Szczepankiewicz D, Hertig I, Skrzypski M, Sassek M, Kaczmarek P, et al. Obestatin inhibits lipogenesis and glucose uptake in isolated primary rat adipocytes. J Biol Regul Homeost Agents. 2013;27(1):23–33. Epub 2013/03/16.
Sayegh AI. The role of cholecystokinin receptors in the short-term control of food intake. Prog Mol Biol Transl Sci. 2013;114:277–316. Epub 2013/01/16.
Seim I, Walpole C, Amorim L, Josh P, Herington A, Chopin L. The expanding roles of the ghrelin-gene derived peptide obestatin in health and disease. Mol Cell Endocrinol. 2011;340(1):111–7. Epub 2011/04/05.
Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res. 2015;2015:157201. Epub 2015/02/18.
Tang SQ, Jiang QY, Zhang YL, Zhu XT, Shu G, Gao P, et al. Obestatin: its physicochemical characteristics and physiological functions. Peptides. 2008;29(4):639–45. Epub 2008/03/08.
Vega GL, Grundy SM. Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. J Obes. 2013;2013:409679. Epub 2013/03/28.
Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. Epub 2012/01/13.
Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science. 2005;310(5750):996–9. Epub 2005/11/15.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Gonzalez-Campoy, J.M. (2019). Hormonal Regulation of Energy Balance and Energy Stores. In: Gonzalez-Campoy, J., Hurley, D., Garvey, W. (eds) Bariatric Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-95655-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-95655-8_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95653-4
Online ISBN: 978-3-319-95655-8
eBook Packages: MedicineMedicine (R0)